Sfoglia per AUTORE
LAUBACH J
Collezione AOU Città della Salute di Torino

  

Items : 5

2022
AOU Città della Salute di Torino

Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legie? W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špi?ka I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;

Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. in British journal of haematology / Br J Haematol. 2022 Feb;196(3):639-648. doi: 10.1111/bjh.17887. Epub 2021 Oct 21.
2022
AOU Città della Salute di Torino

Laubach J; Nadeem O; Mazumder A; Raptis A; Rodriguez-Otero P; Oriol A; Alegre A; Cavo M; Maisel C; Mateos MV; Paner A; Bladé J; Touzeau C; Leleu X; Larocca A; Sandberg A; Orre M; Torrång A; Bakker NA; Richardson PG;

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2021 Mar 1;39(7):757-767. doi: 10.1200/JCO.20.02259. Epub 2020 Dec 9.
2021
AOU Città della Salute di Torino

Laubach JP; Moreb JS; Anderson KC; Raptis A; Mazumder A; Maisel C; Paner A; Alegre A; Hassoun H; Touzeau C; Hiemenz JW; Nadeem O; Leleu X; Rodriguez-Otero P; Cavo M; Bladé J; Larocca A; Oriol A; Richardson PG; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. in The Lancet. Oncology / Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.
2021
AOU Città della Salute di Torino

Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; et alii...

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. in Blood / Blood. 2016 Jun 9;127(23):2833-40. doi: 10.1182/blood-2016-01-694604. Epub 2016 Apr 18.
2016
AOU Città della Salute di Torino

Jakubowiak A; Offidani M; Pégourie B; De La Rubia J; Garderet L; Laribi K; Bosi A; Marasca R; Laubach J; Mohrbacher A; Carella AM; Singhal AK; Tsao LC; Lynch M; Bleickardt E; Jou YM; Robbins M; Palumbo A;